Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical Co., Ltd. scores highest on Torque (95) and lowest on Nitro (11). Its PosiPenta is 46.86 out of 100, around the middle of similar companies.
On the Penta Grid this week, Chugai Pharmaceutical Co., Ltd. is Grid #35 of 49 in Japan.
Compared with similar companies in the Healthcare sector in Japan.
The five pillars
Similar companies
| Company | PosiPenta | P | E | N | T | A |
|---|---|---|---|---|---|---|
| Chugai Pharmaceutical Co., Ltd. | 46.86 | 13 | 56 | 11 | 95 | 59 |
| Daiichi Sankyo Company, Limited | 43.03 | 30 | 46 | 14 | 70 | 54 |
| Shionogi & Co., Ltd. | 57.69 | 70 | 44 | 42 | 69 | 63 |
| Sumitomo Pharma Co., Ltd. | 47.41 | 62 | 32 | 22 | 76 | 44 |
Similar-sized companies in the same sector, this week. P Price · E Earnings · N Nitro · T Torque · A Anchor.
Details
PPrice
| P/E ratio | 23.06 |
| P/B ratio | 5.44 |
EEarnings
| Trailing EPS | ₹175.99 |
| Forward EPS | ₹142.81 |
NNitro
| Price | 4057.76 |
| 52-week high | 6477.40 |
| 52-week low | 3616.45 |
| Fall from 52-week high | 37.4% |
TTorque
| Return on equity (ROE) | 23.49% |
| Debt-to-equity | 0.00 |
AAnchor
| Beta (price swings) | 0.56 |
| Market cap | ₹6,67,735 Cr |
| Insider holding | 59.90% |
| Dividend yield | 1.94% |
Figures as used for the week of 24 Oct 2026; today's figures on the company page may differ slightly.
Questions
What is Chugai Pharmaceutical Co., Ltd.'s PosiPenta score?
Chugai Pharmaceutical Co., Ltd.'s PosiPenta is 46.86 out of 100 for the week of 24 Oct 2026, based on 5 of 5 pillars.
Where does Chugai Pharmaceutical Co., Ltd. stand on the Penta Grid?
On the Penta Grid this week, Chugai Pharmaceutical Co., Ltd. is Grid #35 of 49 in Japan.
Which PosiPenta pillar is strongest for Chugai Pharmaceutical Co., Ltd.?
Torque (durability), with a score of 95 out of 100: much better than most similar companies.
Which PosiPenta pillar is weakest for Chugai Pharmaceutical Co., Ltd.?
Nitro (momentum), with a score of 11 out of 100: much weaker than most similar companies.
PositoAI is for research and education only and is not investment advice.